Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2023-10-20 00:00:00 ET · period of report 2023-10-20 · accession 0000950170-23-054492 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-20 | 2023-10-20 | LAB | Madaus Martin D | Dir | A - Grant | $2.54 | +1,574 | 104.1K | +2% | +$3,998 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-20 | A | A | 1,574 | $2.54 | 104,111 | D | — | — | (F1) Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. (F2) The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board. (F3) Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. |